Omega Pharma, A Perrigo Company

omega-pharma.be

Omega Pharma, the Branded Consumer Healthcare division of Perrigo, is one of the major companies in the consumer health and personal care industry in Europe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

DOTLAB ANNOUNCES TOP-TIER, GLOBAL PHARMACEUTICAL RESEARCH CLIENTS FOR ITS DOTENDO PLATFORM

PR Newswire | January 09, 2024

news image

DotLab, a medical diagnostics company, announced top-tier pharmaceutical research clients for its DotEndo platform. The customers include global companies with interests in diagnosing or monitoring endometriosis on a Research Use Only basis in clinical trial subjects to support the development of new medicines. "We're proud to share the news of our global pharmaceutical partners, which are complementary to our planned, large clinical offering for commercial endometriosi...

Read More

AMAG PHARMACEUTICALS ANNOUNCES CHANGES TO MEDICAL DEVELOPMENT ORGANIZATION

Send Press Releases with GlobeNewswire | March 04, 2020

news image

AMAG Pharmaceuticals, Inc. today announced changes to its medical development organization. Effective March 31, 2020, Julie Krop, M.D., Executive Vice President and Chief Medical Officer, will be leaving the Company. As AMAG initiates a search for a permanent Chief Medical Officer, the Board of Directors and management will continue to work closely with the medical development organization on key priorities, including working with the U.S. Food and Drug Administration (FDA) to find a path to ret...

Read More

Business Insights

NEUROBO PHARMACEUTICALS, INC. AND DONG-A ST CO. LTD. ANNOUNCE STRATEGIC COLLABORATION

NeuroBo Pharmaceuticals, Inc. | September 16, 2022

news image

NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co., Ltd. announced that they have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241 and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis obesity and type 2 diabetes. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucos...

Read More

VIEWS AND ANALYSIS, PHARMACY MARKET

MEDRHYTHMS RECOGNIZED FOR ADVANCEMENTS IN PRESCRIPTION DIGITAL THERAPEUTICS FROM CB INSIGHTS, REUTERS EVENTS PHARMA AND FAST COMPANY

MedRhythms | December 12, 2022

news image

CB Insights today announced that, for the second year in a row, MedRhythms has been named to its annual Digital Health 150, a list that showcases the 150 most promising private digital health companies. This recognition comes a week after MedRhythms received the Most Valuable Digital Therapy award at the Reuters Events Pharma Awards ceremony and less than a month after MedRhythms was named a Fast Company Next Big Things in Tech honoree for the progress that the company has made on its products a...

Read More
news image

RESEARCH

DOTLAB ANNOUNCES TOP-TIER, GLOBAL PHARMACEUTICAL RESEARCH CLIENTS FOR ITS DOTENDO PLATFORM

PR Newswire | January 09, 2024

DotLab, a medical diagnostics company, announced top-tier pharmaceutical research clients for its DotEndo platform. The customers include global companies with interests in diagnosing or monitoring endometriosis on a Research Use Only basis in clinical trial subjects to support the development of new medicines. "We're proud to share the news of our global pharmaceutical partners, which are complementary to our planned, large clinical offering for commercial endometriosi...

Read More
news image

AMAG PHARMACEUTICALS ANNOUNCES CHANGES TO MEDICAL DEVELOPMENT ORGANIZATION

Send Press Releases with GlobeNewswire | March 04, 2020

AMAG Pharmaceuticals, Inc. today announced changes to its medical development organization. Effective March 31, 2020, Julie Krop, M.D., Executive Vice President and Chief Medical Officer, will be leaving the Company. As AMAG initiates a search for a permanent Chief Medical Officer, the Board of Directors and management will continue to work closely with the medical development organization on key priorities, including working with the U.S. Food and Drug Administration (FDA) to find a path to ret...

Read More
news image

Business Insights

NEUROBO PHARMACEUTICALS, INC. AND DONG-A ST CO. LTD. ANNOUNCE STRATEGIC COLLABORATION

NeuroBo Pharmaceuticals, Inc. | September 16, 2022

NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co., Ltd. announced that they have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241 and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis obesity and type 2 diabetes. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucos...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

MEDRHYTHMS RECOGNIZED FOR ADVANCEMENTS IN PRESCRIPTION DIGITAL THERAPEUTICS FROM CB INSIGHTS, REUTERS EVENTS PHARMA AND FAST COMPANY

MedRhythms | December 12, 2022

CB Insights today announced that, for the second year in a row, MedRhythms has been named to its annual Digital Health 150, a list that showcases the 150 most promising private digital health companies. This recognition comes a week after MedRhythms received the Most Valuable Digital Therapy award at the Reuters Events Pharma Awards ceremony and less than a month after MedRhythms was named a Fast Company Next Big Things in Tech honoree for the progress that the company has made on its products a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us